LOX and breast cancer: Two chemically and mechanistically distinct HIF inhibitors, digoxin and acriflavine, were reported to hinder PMN evolution by blocking the hypoxia-induced expression of LOX family proteins, collagen cross-linking and CD11b+ BMDC recruitment, thus preventing lung metastasis in an orthotopic breast cancer model [285].